Document:

<PAGE>

                                                                   EXHIBIT 10.21

                                            ***Text Omitted and Filed Separately
                                                Confidential Treatment Requested
                                            Under 17 C.F.R. (S)(S) 200.80(b)(4),
                                                            200.83 and 240.24b-2

                           MEMORANDUM OF MODIFICATIONS
                       TO KIRIN AND DENDREON COLLABORATION

                                                                  AUGUST 2, 2001

Background Statement

Kirin and Dendreon, in the course of reviewing their on-going collaboration for
the development and marketing of vaccines employing Dendreon's proprietary
dendritic cell technology, agree to make certain modifications to that
collaboration relating to payments by Kirin and certain support provided to
Kirin by Dendreon.

Amendment

This Memorandum confirms and memorializes the intention of Dendreon and Kirin to
amend their collaboration as set forth in that certain Collaborative License
Agreement dated December 10, 1998, the Research And License Agreement dated
February 1, 1999, the Manufacture And Supply Agreement dated June 27, 1999 and
the Joint Commercialization Agreement dated February 1, 2000 between Kirin and
Dendreon ("the Agreements"). Kirin and Dendreon shall use their reasonable best
efforts to finalize appropriate amendments by December 31, 2001. Until such
amendments are finalized and executed by both Dendreon and Kirin, the following
Agreed Matters shall be binding upon the parties. To the extent a conflict
arises between the terms of the Agreements and the Agreed Matters, the Agreed
Matters shall prevail but only to the extent necessary to accomplish the
intended purpose.

Agreed Matters

Kirin and Dendreon agree as follows (Capitalized terms used, but not defined
herein, shall have the meanings ascribed thereto in the Agreements):

     1.   Kirin will pay Dendreon US$10MM on or before August 7, 2001.

     2.   Kirin will pay Dendreon [...***...] upon commencement of Kirin's first
          clinical study as described below of APC8020 in Japan.

          2.1  "Commencement" for purposes of when this payment is due means the
               date on which the first patient in this clinical study to receive
               therapy begins to receive therapy, that is, when the first
               apheresis is performed.

          2.2  This clinical study is scheduled to commence not later than March
               1, 2002; Kirin and Dendreon recognize that in order to

                                               *Confidential Treatment Requested

                                                                               1

<PAGE>

               meet this scheduled commencement date, Kirin must first have its
               Kakunin-Shinsei (Confirmation Application for safety and quality)
               confirmed by the Japan Ministry of Health, Labor and Welfare (the
               "Ministry") and must file its IND with the Ministry. Kirin will
               use its Reasonable Efforts and, as agreed below and in the
               Agreements, Dendreon will support Kirin's Reasonable Efforts, to
               meet this scheduled commencement date. Failure of Kirin to meet
               the scheduled commencement date, despite its Reasonable Efforts,
               shall not be considered a breach by Kirin of the Agreements.

          2.3  Once the [...***...] payment has been made, such [...***...]
               payment will be considered full payment in satisfaction of the
               PHase II milestone payment for APC8020 required by Section 5.5 of
               the Collaborative License Agreement whether or not the Ministry
               considers Kirin's first clinical study a Phase II study.

     3.   The transfer price for Kirin's purchase of PA2024 from Dendreon, until
          Dendreon's obligation to furnish PA2024 terminates pursuant to Section
          5.3 hereof, shall be as follows:

          3.1  For PA2024 manufactured up to and at the 2000L scale, a transfer
               price in an amount in U.S. dollars equal to the Fully Burdened
               Manufacturing Costs of PA2024 at the time of manufacture, plus a
               handling fee of [...***...].

               3.1.1 Notwithstanding that from time to time Dendreon scales up
                     the manufacture of PA2024 to greater than 2000L scale, the
                     transfer price of PA2024 shall be an amount in U.S. dollars
                     equal to the Fully Burdened Manufacturing Costs of PA2024
                     at the time Dendreon last manufactures or has manufactured
                     PA2024 at the 2000L scale, plus a handling fee of
                     [...***...].

               3.1.2 The transfer price shall be exclusive of any scale-up costs
                     of PA2024 and shall not include any factor for Dendreon's
                     costs of scale-up of PA2024 to the 2000L scale.

          3.2  In the event that from time to time Dendreon scales up the
               manufacture of PA2024 to greater than 2000L scale, Kirin may
               elect in writing to purchase PA2024 from Dendreon at a transfer
               price in U.S. dollars equal to the Fully Burdened Manufacturing
               Costs of PA2024 at the time of manufacture at such greater scale,

                                               *Confidential Treatment Requested

                                                                               2

<PAGE>

               plus a handling fee of [...***...]. Prior to each such election,
               Kirin may notify Dendreon in writing of Kirin's good faith
               tentativE intention to make an election, and request a statement
               from Dendreon of the actual scale-up costs to Dendreon of the
               scale-up. Dendreon shall furnish Kirin with a statement of such
               scale-up costs. Dendreon shall furnish Kirin, at Kirin's request,
               periodic progress reports on such scale-up efforts.

               3.2.1 The transfer price shall be exclusive of any scale-up costs
                     of PA2024 and shall not include any factor for Dendreon's
                     costs of scale-up of PA2024 to such greater scale.

               3.2.2 At the time of each such election, Kirin shall reimburse to
                     Dendreon [...***...] of the documented costs to Dendreon of
                     the scale-up to which the election relates, to include
                     [...***...] of the documented costs to Dendreon of aNy
                     lesser scale-up not previously reimbursed.

     4.   Kirin may purchase Dendreon's Separation Devices from Dendreon for use
          in connection with APC8015 and APC8020 for a transfer price in an
          amount in U.S. dollars equal to the Fully Burdened Manufacturing Costs
          of the Separation Devices, plus a handling fee of [...***...]. At no
          additional cost to Kirin, Kirin shall be deemed to have (a) exercised
          its option to proviDe financial support for APC8015 and APC8020 within
          the meaning of Section 5.3 of the Manufacturing And Supply Agreement
          and (b) have provided its full share of such financial support for
          purposes of fixing the transfer price of the Separation Devices for
          use in connection with APC8015 and APC8020.

     5.   Dendreon shall, upon Kirin's request, grant to Kirin, free of charge,
          a non-exclusive license, with the right to sub-license, to manufacture
          PA2024 for use in ways permitted by the Agreements; such license shall
          include a right to use manufacturing technology and know-how owned or
          controlled by Dendreon as of March 16, 2001. Such manufacture and/or
          use shall not interfere with Kirin's use of Reasonable Efforts to
          develop, obtain Regulatory Approval in the Kirin Territory for, and
          market and sell in the Kirin Territory APC8015. Upon the grant of such
          license and within a commercially reasonable time, but no longer than
          90 days, after Kirin's written request, Dendreon shall transfer to
          Kirin the manufacturing technology and know-how so licensed, provided,
          that the manufacturing technology and know-how transferred under such
          license shall be limited to the manufacturing technology and know-how
          owned or controlled by Dendreon as of March 16, 2001.

                                               *Confidential Treatment Requested

                                                                               3

<PAGE>

          5.1  The term of the license will be the later of (a) the expiration
               of the term of the Collaborative License Agreement, or (b) until
               Kirin has ceased all activity in connection with PA2024 permitted
               herein; provided, however, that in the event of an uncured
               material breach by Kirin of the Collaborative License Agreement
               as contemplated in Section 11.2 thereof, the license and
               sub-license(s) shall terminate as provided therein, and in the
               event of a termination without cause of the Collaborative License
               Agreement as provided in Section 11.5 thereof, the license and
               sub-license(s) shall terminate upon termination of the
               Collaborative License Agreement.

          5.2  Subject to the terms of the license, Kirin may manufacture PA2024
               anywhere worldwide so long as such manufacturing does not
               conflict with any activities of Dendreon or obligations of
               Dendreon to any third party.

          5.3  Any obligation of Dendreon to furnish PA2024 to Kirin shall
               terminate three years after the grant of the license. In the
               absence of a grant of such license, Dendreon's obligation to
               furnish Kirin PA2024 shall continue to be as set forth in the
               Agreements.

          5.4  Dendreon agrees, upon Kirin's request, to discuss with Kirin with
               respect to Kirin's non-exclusive license to use manufacturing
               technology and know-how that is owned or controlled by Dendreon,
               and that is greater than Dendreon's manufacturing scale as of
               March 16, 2001.

     6.   In the event Kirin develops improvements to the process for
          manufacturing PA2024, Dendreon shall have an option to take from Kirin
          an exclusive, assignable, sublicensable, royalty-free license and the
          technology pertaining thereto to make, sell and use for all purposes,
          any of such improvements outside the Kirin Territory. An option fee,
          which shall be due and payable within thirty days of each exercise of
          the option, shall be an amount in U.S. dollars equal to [...***...] of
          the documented cost to Kirin of developing the improvement as to which
          the option is exercised, and the term of such license will be the
          later of (a) expiration of the Collaborative License Agreement, or (b)
          until Dendreon has ceased all activity in connection with such
          improvement(s) permitted herein; provided, however, that in the event
          of an uncured material breach by Dendreon of the Collaborative License
          Agreement as contemplated in Section 11.2 thereof, the license(s)
          shall terminate as provided therein.

                                               *Confidential Treatment Requested

                                                                               4

<PAGE>

     7.   Dendreon shall provide extraordinary support to Kirin relating to
          Kirin's regulatory, clinical and manufacturing activities pertaining
          to APC8015 and APC8020. Extraordinary support is support over and
          above sharing of information relating to patent prosecution and other
          proceedings, information sharing relating to Kirin's activities and
          assistance relating to the transfer of technology to Kirin, and
          activities associated with the Steering Committee, as contemplated in
          Sections 8.2 and 10.1 and Article 3 of the Collaborative License
          Agreement, respectively, and activities of the Joint Research
          Committee as contemplated in Article 2 of the Research And License
          Agreement; extraordinary support is support that which, in comparison
          to the furnishing of information and support under the Agreements, may
          include one or more of the features of being significantly more time
          consuming, travel, increased urgency, repeat training, certain on site
          visits and active assistance. Examples of extraordinary support are
          set forth on Schedule A.

          7.1  The period during which Dendreon will provide such extraordinary
               support to Kirin is until each of APC8015 and APC8020 have been
               either finally approved or finally rejected for commercial use in
               Japan by the Ministry or until December 31, 2004, whichever
               occurs sooner.

          7.2  Dendreon shall provide such extraordinary support as requested by
               Kirin and Kirin shall endeavor to make each of its requests
               reasonable from the standpoint of both time of requested response
               and content. If Dendreon determines in good faith that to provide
               particular extraordinary support would be unduly burdensome and
               would work a substantial hardship on Dendreon, Dendreon may
               decline to provide such extraordinary support so long as Dendreon
               offers to provide alternative extraordinary support in a manner
               and at a time reasonable under the circumstances.

          7.3  Dendreon and Kirin will each assign one or more of their
               respective employees the duty of liaison between Kirin and
               Dendreon for handling requests for extraordinary support from
               Kirin. Members of functional groups of Kirin and Dendreon
               respectively, will communicate with each other in the normal and
               ordinary course of their activities as functional group members.

          7.4  Kirin will reimburse Dendreon for Dendreon's out of pocket
               expenses relating to extraordinary support, limited to airfare,

                                                                               5

<PAGE>

               ground transportation, food and lodging and shipping expenses
               incidental to providing extraordinary support.

     8.   During the term of the Collaborative License Agreement, Dendreon shall
          provide to Kirin copies, in paper and/or electronic form, to the
          extent compiled in the ordinary course of Dendreon's clinical trial
          management, and to the extent Dendreon may do so free of any
          prohibiting law or regulation and any claim or right of another, all
          information pertinent to Dendreon's development and regulatory
          activities for both APC8015 and APC8020, including raw data supporting
          conclusory documents. By way of non-limiting example, if Dendreon
          prepares a clinical report, Dendreon shall provide a copy of such
          report together with supporting raw data within a commercially
          reasonable period of time after such report is prepared and after it
          is permissible to furnish it to Kirin. The providing of such
          information in the manner set forth in this Section 8 shall not be
          considered extraordinary support.

          8.1  Recognizing that the approval of Dendreon Licensed Products in
               the Kirin Territory is important to both Kirin and Dendreon, in
               the event the Ministry or an equivalent governmental agency in a
               country other than Japan in the Kirin Territory makes a written
               request of Kirin to furnish information pertinent to Dendreon's
               development and regulatory activities for APC8015 and/or APC8020
               that is proprietary to a third party, and which Dendreon would
               otherwise be required to provide under Section 8, Dendreon shall,
               upon request by Kirin, use reasonable best efforts to negotiate
               for the right of Kirin, to have access to such information for
               regulatory compliance purposes only, or alternatively to have
               such information furnished directly to the Ministry or equivalent
               governmental agency. For purposes of this Sub-section 8.1, such
               information generated in an on-going process of development, such
               as the scale-up of antigen, shall be deemed not to be information
               as to which Dendreon's obligation in this Sub-section 8.1
               applies.

     9.  Kirin and Dendreon will furnish each other with a summary of their
         respective plans relating to APC8015 and APC8020 at the beginning of
         each calendar year for that year, including for information purposes
         only, general budget information, clinical goals and action plans, and
         will provide to each other periodic reports (that is, at least one
         every six months) against those goals and plans, including for
         information purposes only, an indication of whether spending of
         budgeted funds is consistent with plans.

                                                                               6

<PAGE>

     10.  The milestone payment provided for in the Collaborative License
          Agreement for Kirin's commencement of a Phase II clinical trial of
          APC8015 is unaffected by the agreements made in this memorandum.
          "Commencement" for purposes of when this payment is due means the date
          on which the first patient to receive therapy in this clinical study
          begins to receive therapy, that is, when the first apheresis is
          performed.

     11.  Milestone payments provided for in the Collaborative License Agreement
          arising upon the exercise of options by Kirin on products other than
          APC8015 and APC8020 are unaffected by the agreements made in this
          memorandum.

     12.  The Full Time Equivalent payments Kirin is making to Dendreon are
          unaffected by the agreements made in this memorandum but the parties
          may agree to reallocate FTEs.

          Dated:  August 3, 2001                 Dated:  August 3, 2001

          Kirin Brewery Co., Ltd.                Dendreon Corporation

          By:  Katsuhiko Asano                   By:  Christopher S. Henney

               President                              Chairman and Chief
               Pharmaceutical Division                Executive Officer

                                                                               7

<PAGE>

                        EXAMPLES OF EXTRAORDINARY SUPPORT

Regulatory

Dendreon, at Kirin's request, sends one or more Dendreon employees to Japan to
assist Kirin in a meeting with the Ministry.

Dendreon, at Kirin's request, answers questions that are posed by the Ministry
relating to a Kirin Kakunin-Shinsei.

Dendreon, at Kirin's request, provides substantial documentation in a relatively
short time period to support a Kirin Kakunin-Shinsei.

Manufacturing

Dendreon, at Kirin's request, send one or more Dendreon employees to Japan to
inspect Kirin's cell processing center.

Dendreon, at Kirin's request, reviews and analyzes Kirin's quality control
procedures or data.

Dendreon, at Kirin's request, provides repeat training of Kirin personnel.

Clinical

Dendreon, at Kirin's request, sends one or more Dendreon employees to Japan to
assist Kirin in a meeting of Kirin investigators.

Dendreon, at Kirin's request, reviews and analyzes Kirin clinical data.

Dendreon, at Kirin's request, on relatively short deadline, gathers and explains
Dendreon clinical data.

                                                                               8<PAGE>

                                                                    EXHIBIT 10.9

                       THIRD AMENDMENT TO CREDIT AGREEMENT

Dated as of:   September 25, 2001

Parties:       StanCorp Financial Group, Inc,
               an Oregon corporation                                ("Borrower")

               U. S. Bank National Association                     ("U.S. Bank")

                                    RECITALS

     A. U.S. Bank and Borrower have entered into a Credit Agreement dated June
30, 2000 ("Credit Agreement"), a First Amendment to Credit Agreement dated June
27th, 2001 ("First Amendment"), and a Second Amendment to Credit Agreement dated
July 31, 2001, ("Second Amendment;" collectively, "Credit Agreement, as
amended").

     B. The parties wish to modify the Credit Agreement as amended, as set forth
herein.

     NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties agree to enter into this Third
Amendment to Credit Agreement ("Third Amendment") as follows:

1.   All capitalized terms used in this Third Amendment and not defined herein
shall have the meanings assigned to those terms in the Credit Agreement
as amended.

2.   The reference to "$200,000,000" in Section 9.7 is hereby deleted and
replaced by "$250,000,000."

3.   The effectiveness of this Third Amendment is subject to satisfaction of the
following conditions precedent prior to or concurrently with the execution of
this Third Amendment:

         3.1   No Event of Default shall have occurred and be continuing.

         3.2   All representations and warranties contained in the Credit
Agreement as amended shall be true and correct as of the date of execution of
this Third Amendment.

         3.3   U.S. Bank shall have received such other documents and
information and Borrower shall have satisfied such additional requirements,
as U.S. Bank reasonably requires.

4.   Borrower reaffirms the representations and warranties in the Credit
Agreement as amended and in the Loan Documents and acknowledges that except
as amended herein, each such Loan Document remains in full force and effect and
is and shall remain valid and enforceable in accordance with its terms.
Following the execution of this Third Amendment, references in the Credit
Agreement to the "Agreement" mean the Credit Agreement as amended by the First
Amendment, the Second Amendment, and the Third Amendment.

                                     Page 1

<PAGE>

5.   DISCLOSURE. Under Oregon law, most agreements, promises and commitments
made by lenders after October 3, 1989, concerning loans and other credit
extensions which are not for personal, family or household purposes or secured
solely by the borrower's residence must be in writing, express consideration and
be signed by the lender to be enforceable.

    Borrower and Guarantors acknowledge receipt of a copy of this Agreement.

STANCORP FINANCIAL GROUP, INC.              U.S. BANK NATIONAL ASSOCIATION

By: /s/ Cindy J. McPike                     By: /s/ Laine Wright

Title: Vice President, Controller           Title: Vice President, Relationship
       and Treasurer                               Manager

                      CONSENT AND REAFFIRMATION OF GUARANTY

Each of the undersigned hereby acknowledges and agrees to all terms and
conditions of the foregoing Third Amendment to Credit Agreement, acknowledges
and consents to the execution, delivery and performance by StanCorp Financial
Group, Inc. of this Third Amendment to Credit Agreement. In addition each of the
undersigned reaffirms his obligation to U.S. Bank National Association and
agrees that all terms and conditions of the Guaranty dated
___________________________________ shall remain in full force and effect.

Standard Insurance Company                  StanCorp Mortgage Investors, LLC

By:   /s/ Eric E. Parsons                   By:   /s/ Eric E. Parsons

                                                  StanCorp Financial Group, Inc.

Its:  Senior Vice President and             Its:  Member

      Chief Financial Officer

Date: October 5, 2001                       Date: October 5, 2001

                                     Page 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]